Investors bought shares of Amgen Inc. (NASDAQ:AMGN) on weakness during trading on Thursday. $144.62 million flowed into the stock on the tick-up and $79.81 million flowed out of the stock on the tick-down, for a money net flow of $64.81 million into the stock. Of all companies tracked, Amgen had the 8th highest net in-flow for the day. Amgen traded down ($0.26) for the day and closed at $189.44
Several brokerages have recently commented on AMGN. UBS AG restated a “neutral” rating and set a $175.00 price objective (up from $174.00) on shares of Amgen in a research report on Tuesday, June 13th. Royal Bank Of Canada began coverage on shares of Amgen in a research report on Thursday. They set a “sector perform” rating and a $192.00 price objective on the stock. BMO Capital Markets restated a “buy” rating and set a $198.00 price objective (down from $200.00) on shares of Amgen in a research report on Monday, May 22nd. Morgan Stanley raised their price objective on shares of Amgen from $183.00 to $184.00 and gave the company an “overweight” rating in a research report on Tuesday, June 13th. Finally, Oppenheimer Holdings, Inc. restated an “outperform” rating and set a $203.00 price objective (up from $189.00) on shares of Amgen in a research report on Wednesday, July 26th. One investment analyst has rated the stock with a sell rating, twelve have given a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $186.14.
The stock has a market capitalization of $136.79 billion, a PE ratio of 17.08 and a beta of 1.35. The company has a 50-day moving average price of $175.31 and a 200-day moving average price of $169.32.
Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, July 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.11 by $0.16. Amgen had a net margin of 35.46% and a return on equity of 29.85%. The firm had revenue of $5.81 billion during the quarter, compared to analyst estimates of $5.67 billion. During the same quarter in the prior year, the firm posted $2.84 earnings per share. Amgen’s quarterly revenue was up 2.1% on a year-over-year basis. Equities analysts predict that Amgen Inc. will post $12.57 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which was paid on Friday, September 8th. Investors of record on Thursday, August 17th were issued a $1.15 dividend. This represents a $4.60 dividend on an annualized basis and a dividend yield of 2.45%. The ex-dividend date was Tuesday, August 15th. Amgen’s dividend payout ratio is currently 41.93%.
Several institutional investors and hedge funds have recently made changes to their positions in AMGN. Janus Henderson Group PLC grew its holdings in shares of Amgen by 3,664.7% in the second quarter. Janus Henderson Group PLC now owns 3,699,351 shares of the medical research company’s stock valued at $637,139,000 after purchasing an additional 3,601,087 shares during the period. FMR LLC grew its holdings in shares of Amgen by 4.8% in the second quarter. FMR LLC now owns 56,999,572 shares of the medical research company’s stock valued at $9,817,037,000 after purchasing an additional 2,587,041 shares during the period. Renaissance Technologies LLC grew its holdings in shares of Amgen by 40.9% in the second quarter. Renaissance Technologies LLC now owns 3,400,145 shares of the medical research company’s stock valued at $585,607,000 after purchasing an additional 986,700 shares during the period. BlackRock Inc. grew its holdings in shares of Amgen by 1.9% in the second quarter. BlackRock Inc. now owns 49,451,203 shares of the medical research company’s stock valued at $8,516,980,000 after purchasing an additional 909,689 shares during the period. Finally, Nordea Investment Management AB grew its holdings in shares of Amgen by 12.9% in the second quarter. Nordea Investment Management AB now owns 7,040,599 shares of the medical research company’s stock valued at $1,212,602,000 after purchasing an additional 806,119 shares during the period. 78.14% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: “Traders Buy Amgen Inc. (AMGN) on Weakness” was first posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this news story can be viewed at https://www.chaffeybreeze.com/2017/09/16/traders-buy-amgen-inc-amgn-on-weakness.html.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.